1. 首次體驗優惠只適用於從未體驗過及未曾購買過升級版冷凍溶脂之18 歲或以上之客戶。 2. 如有任何爭議，NEO DERM Group Limited 保留最終決定權。 - Study conducted July 2009 – January 2011 (n=112), with 85 patients available for follow-up calliper evaluations. The average fat reduction at follow-up was 21.5%. The 27% reduction refers specifically to the lower abdomen (n=55). Average reductions in other treatment areas included: brassiere rolls 20% (n=4), lumbar rolls 22% (n=2), hip rolls 25% (n=20), inner thighs 17% (n=3), and medial knees 18% (n=1). Patients were treated at one or more sites for a total of ≤four treatment areas in a single session. - Termed Cryolipolysis®, this technology enables a non-invasive alternative for subcutaneous fat reduction through cellular apoptosis.The CoolSculpting® products are covered by the United States patents (Patent No. US 7,367,341) and foreign equivalents. - Andrew A. Nelson; Daniel Wasserman; Mathew M. Avram (2009). Cryolipolysis for Reduction of Excess Adipose Tissue. , 28(4), 0–249. doi:10.1016/j.sder.2009.11.004 - All time International Cycles Summary_040621. Data sourced from Connect Cube database. May 2021 - CoolSculpting® and CoolSculpting® Elite are FDA-cleared for the treatment of visible fat bulges in the submental (under the chin) and submandibular (under the jawline) areas, thigh, abdomen, and flank, along with bra fat, back fat, underneath the buttocks (also known as banana roll), and upper arm. It is also FDA-cleared to affect the appearance of lax tissue with submental area treatments - The percentage increase is calculated by working out the cooling surface difference between CoolAdvantageTM family applicators and their respective next-generation applicators, dividing this by the CoolAdvantageTM family applicator surface and then multiplying the result by 100. - Based on a comparison between the weight of the CoolSculpting® ELITE F165™ applicator (1.6 lb) and the CoolAdvantage™ CoolCurve+ applicator (3.8 lb), both without umbilicals.